Acute toxicity and the hypoglycemic action of n,n΄-(ethane-1,2-dyyil)bis(quinoline-2-carboxamide)

Authors

  • O. N. Kalapko National University of Pharmacy, Ukraine
  • S. Yu. Shtrygol` National University of Pharmacy, Ukraine
  • B. V. Paponov V.N.Karazin Kharkiv National University, Ukraine
  • S. V. L’vov V.N.Karazin Kharkiv National University, Ukraine

DOI:

https://doi.org/10.24959/cphj.14.1303

Keywords:

N, N΄-(ethane-1, 2-dyyil)bis(quinoline-2-carboxamide), acute toxicity, hypoglycemic effect, diabetes mellitus, therapeutic index, alloxan

Abstract

The results of the study of N,N΄-(ethane-1,2-dyyil)bis(quinoline-2-carboxamide) as a potential hypoglycemic agent on the model of alloxan diabetes, as well as in normoglycemic rats are presented, the “dose – effect” relationship and acute toxicity in various routes of administration have been determined. Proceeding from the theory of pharmacophores the test compound can be considered as a dimer of 2-(4,5-dihydroimidazol-2-yl)quinoline hydrochloride (BU 224), a blocker of I2-imidazoline receptors, but it is not a dimer in terms of organic chemistry. It has a strong hypoglycemic effect in intragastric administration in the dose range of 7.92-31.67 mg/kg. The maximum hypoglycemic effect is provided by the dose of 15.84 mg/kg. ED50 equals 11.64 mg/kg, the therapeutic index is 54.42 indicating a sufficient breadth of the therapeutic effect and safety of the test compound. In normoglycemia N,N΄-(ethane-1,2-dyyil)bis(quinoline-2-carboxamide) decreases the blood glucose level at the dose of 15.84 mg/kg, while the doses of 3.96 mg/kg and 7.92 mg/kg do not affect the blood glucose level, and it indicates that the features of pharmacodynamics and the hypoglycemic effect depend on the state of the carbohydrate metabolism. It has been shown that in hyperglycemia the hypoglycemic effect is observed starting at the dose of 7.92 mg/kg, and higher doses. However, in healthy animals, the aforesaid dose does not affect the blood glucose level. In the intraperitoneal administration the hypoglycemic effect is evident at the lower dose of 1.5 mg/kg exceeding metformin at the dose of 100 mg/kg by its hypoglycemic activity. In the intraperitoneal administration N,N΄-(ethane-1,2-dyyil)bis(quinoline-2-carboxamid) belongs to moderately toxic substances (toxicity of class III, LD50 = 10.005 mg/kg), in the intragastric administration – to low-toxic substances (toxicity of class IV, LD50 = 633.45 mg/kg).

References

Балаболкин М.И. Диабетология. – М.: Медицина, 2000. – 471 с.

Доклінічні дослідження лікарських засобів: Метод. рекоменд. / За ред. чл.-кор. НАМН України, акад. О.В.Стефанова. – К.: Авіценна, 2001. – 400 с.

Руководство по проведению доклинических исследований лекарственных средств / Под ред. докт. мед. наук А.Н.Миронова. – М.: Гриф и К, 2012. – Ч. І. – 944 с.

Cheng J.T., Huang C.C., Liu I.M. et al. // Diabetes. – 2006. – Vol. 55. – P. 819-825.

Dave K.R., Katyare S.S. // J. оf Endocrinol. – 2002. – Vol. 175, №1. – Р. 241-250.

Echeverria M., Mendivil B., Cordeuetal L. // Arch. Pharm. Chem. Life Sci. – 2006. – Vol. 339. – P. 182-192.

Huang S., Zhong R., Liang M. // China J. Mod. Med. – 2004. – Vol. 14, №17. – P. 34-36.

Kekalainen P., Sarlund H., Pyorala K. // Diabetes Care. – 1999. – Vol. 22, №1. – P. 86-92.

Lebovitz H.Е., Austin M.M., Blonde L. et al. // Endocr. Pract. – 2006. – Vol. 12 (Suppl. 1). – P. 6-12.

Lee J.P., Chen W., Wu H.T. еt al. // Horm. Metab. Res. – 2011. – Vol. 43, №1. – P. 26-30.

Ong K.L., Cheung B.M., Wong L.Y. et al. // Ann. Epidemiol. – 2009. – Vol. 18. – P. 222-229.

Downloads

Published

2014-06-10

Issue

Vol. 18 No. 2 (2014)

Section

Pre-clinical studies of new drugs

License

Copyright (c) 2014 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).